Candel Therapeutics Inc. (NASDAQ: CADL) will present extended follow-up data from its Phase 3 trial of aglatimagene besadenovec in localized ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE